anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
BACKGROUND: The occurrence of severe intraventricular hemorrhage (sIVH) was high in the very preterm infants (VPIs) in China. The management strategies significantly contributed to the occurrence of sIVH in VPIs. However, the status of the perinatal strategies associated with sIVH for VPIs was rarely described across the multiple neonatal intensive care units (NICUs) in China. We aim to investigate the characteristics of the perinatal strategies associated with sIVH for VPIs across the multiple NICUs in China.
METHODS: This was a retrospective analysis of data from a prospective cohort of Chinese Neonatal Network (CHNN) dataset, enrolling infants born at 24+0-31+6 from 2019 to 2021. Eleven perinatal practices performed within the first 3 days of life were investigated including antenatal corticosteroids use, antenatal magnesium sulphate therapy, intubation at birth, placental transfusion, need for advanced resuscitation, initial inhaled gas of 100% FiO2 in delivery room, initial invasive respiratory support, surfactant and caffeine administration, early enteral feeding, and inotropes use. The performances of these practices across the multiple NICUs were investigated using the standard deviations of differences between expected probabilities and observations. The occurrence of sIVH were compared among the NICUs.
RESULTS: A total of 24,226 infants from 55 NICUs with a mean (SD) gestational age of 29.5 (1.76) and mean (SD) birthweight of 1.31(0.32) were included. sIVH was detected in 5.1% of VPIs. The rate of the antenatal corticosteroids, MgSO4 therapy, and caffeine was 80.0%, 56.4%, and 31.5%, respectively. We observed significant relationships between sIVH and intubation at birth (AOR 1.52, 95% CI 1.13 to 1.75) and initial invasive respiratory support (AOR 2.47, 95% CI 2.15 to 2.83). The lower occurrence of sIVH (4.8%) was observed corresponding with the highest utility of standard antenatal care, the lowest utility of invasive practices, and early enteral feeding administration.
CONCLUSIONS: The current evidence-based practices were not performed in each VPI as expected among the studied Chinese NICUs. The higher utility of the invasive practices could be related to the occurrence of sIVH.
A growth-promoting supplement for livestock is a meal additive for hair growth, tail growth, and nail growth. The growth-promoting supplement also promotes hair, tail, and nail strength. The growth-promoting supplement includes a quantity of gelatin, a quantity of Biotin, a quantity of Lysine, a quantity of Vitamin E, and a quantity of Methionine. The composition is heterogeneously mixed into a powdered mixture that may be mixed into a meal for livestock. The composition further includes a quantity of alfalfa powder. Alternatively, the composition further includes a quantity of current-health-based additives. The current-health-based additives includes a quantity of Vitamin C, a quantity of Zinc, a quantity of Omega-3 fatty acids, and combinations thereof. Both the quantity of alfalfa powder and the quantity of current-health-based additives are heterogeneously mixed into the powdered mixture according the specific dietary needs and health condition of the livestock.
This double-blind, randomized, controlled, cross-over study on healthy participants will evaluate the perceptual differences of pain and changes in mood in response to peripheral nerve stimulation over two regions of the left external ear. A series of short and long duration heat stimuli will be applied to the participants forearms and they will be asked to rate their current mood state, the intensity of the pain, and whether it was pleasant or unpleasant. The series of heat stimuli will be applied before, during, and after mild electrical stimulation of the left external ear using a commercially available TENS unit. There are two study sessions. Session 1 involves eligibility screening, a brief practice session, followed by the testing session. In Session 2 (no more than 7 days later), the testing session will be repeated with the exception of the location of ear stimulation. Up to 76 people, ages 18-50 years old, will be enrolled in the study.
Combination therapy with glimepiride and insulin may also be used in secondary failure patients. The fasting glucose level for instituting combina­tion therapy is in the range of >150 mg/dL in plasma or serum depending on the patient. The recommended glimepiride dose is 8 mg once daily admin­istered with the first main meal. After starting with low-dose insulin, upward adjustments of insulin can be done approximately weekly as guided by frequent measurements of fasting blood glucose. Once stable, combination-therapy patients should monitor their capillary blood glucose on an ongoing basis, preferably daily. Periodic adjustments of insulin may also be necessary during maintenance as guided by glucose and HbA1c levels.
Patients receive doxorubicin hydrochloride IV on day 1 and sorafenib tosylate PO QD or BID on days 1-21. Treatment repeats every 21 days for 6 courses in the absence of disease progression or unacceptable toxicity. After 6 courses, patients may continue to receive sorafenib tosylate PO QD or BID in the absence of disease progression or unacceptable toxicity.
Propofol-based anesthetic maintenance with ephedrine used as the vasopressor. Patient will receive propofol as their maintenance agent during surgery. The typical dose is 150-200 mg/kg/min. The patient will receive ephedrine infusion as the primary vasopressor of choice. The typical dose of ephedrine infusion is 10-50 mg/hr (dilution 2 mg/ml).
Treatment provided in eight individual sessions of 60 min., Once a week by videoconference. The integrity of the treatment will be controlled through the therapist's manual (Barlow et al., 2011) adapted for the Mexican population and to the online modality.
<P>PROBLEM TO BE SOLVED: To provide a new receptor for human parvovirus B19 other than P antigen and to provide a reagent for assaying and adsorbing the human parvovirus B19 and an infection inhibitor utilizing the receptor for the human parvovirus B19.  <P>SOLUTION: A Ku80 protein is the receptor for the human parvovirus B19. The receptor for the human parvovirus B19 is composed of the Ku80. A binder for the human parvovirus B19 is composed of the Ku80. Furthermore, the infection inhibitor of the human parvovirus B19 comprises a substance inhibiting the binding of the Ku80 to the human parvovirus B19 or its binding fragment as an active ingredient.  <P>COPYRIGHT: (C)2005,JPO&NCIPI
A method and kit for providing a tack-free artificial nail surface. The tack-free artificial nail surface may include an acrylic layer and a barrier layer. The acrylic layer may comprise an odorless monomer. The barrier layer may be of any material impervious to oxygen. The tack-free nail surface may be formed by application of the acrylic layer to a fingernail nail bed. The barrier layer may then be applied over the acrylic layer. The barrier layer blocks oxygen from the acrylic layer so that the acrylic layer may polymerize in the absence of oxygen.
The present invention addresses the problem of providing a novel skin collagen production-promoting agent for promoting the biosynthesis of skin collagen, which is capable of preventing dry skin, rough skin, wrinkles and sagging, and can also be used as a food material without any safety problems. The present invention also addresses the problem of providing foods, drinks and cosmetic materials containing the skin collagen production-promoting agent. The skin collagen production-promoting agent uses milk protein fractions having the following characteristics (a) to (c) as the active ingredient. (a) The milk protein fractions are derived from milk. (b) The fractions, obtained by sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE), contain proteins with molecular masses ranging from 12,000 to 16,000 daltons. (c) The constituent amino acid composition contains 18 to 20 wt % basic amino acids, and the ratio of basic amino acids/acidic amino acids ranges from 0.7 to 0.9.
Various forms of metal nanoparticle agglomerates can be used to facilitate infection control. The antimicrobial substrate may include a base substrate and agglomerates of metal nanoparticles adhered to the base substrate. The agglomerates of metal nanoparticles on the antimicrobial substrate may be contacted with skin penetration, skin injury, burn, site to be subjected to skin penetration, or active skin infection site, providing infection control against at least one pathogen. In some cases, the antimicrobial substrate may also promote water purification. An antimicrobial fluid formulation comprising a fluid medium in which agglomerates of metal nanoparticles are dispersed may be configured for topical or oral use and may similarly provide infection control. Creams, ointments, balms, salves, gels, and liquids or liquid suspensions containing agglomerates of metal nanoparticles may be effective to promote infection control and/or treat active infections.
Transcutaneous application of high frequency electrical current over the arm for a 30 minutes session. The intensity of the current will increase until participants report a "strong but comfortable" sensation, just below motor threshold.
Adult participants will receive seltorexant once daily from Day 1-7 and together with matching placebo from Day 8 till Day 182. Elderly participants will receive seltorexant once daily from Day 1-3 and together with matching placebo from Day 4 till Day 182.
PURPOSE:To obtain the subject glass powder substantially extending operational time without having adverse effects on the physical properties of cured cement by mixing glass powder with a carboxylic acid in the presence of water followed by heat treatment. CONSTITUTION:Aluminosilicate glass powder to be used as a powder component for glass ionomer cement for dental use is incorporated with <=0.1 (pref. >=0.3)wt.% of a carboxylic acid (pref. tartaric acid) in the form of a 1-10wt./ vol.% aqueous solution. The mixture is then treated under heating at 100-400 (pref. 150-250) deg.C for 4-24hr. The resultant glass powder heat-treated is kneaded with a polyalkenic acid in the presence of water to carry out reaction and setting to prepare glass ionomer cement for dental use.
A polynucleotide encoding a human vault-associated vRNA or its complementary strand. A purified and isolated polynucleotide molecule consisting essentially of a human vault RNA, or its complementary strands, or a combination of a nucleotide sequence consisting essentially of a human vault RNA and its complementary strands. A method of diagnosing a patient with a multidrug-resistant cancer. A method of treating a patient with multidrug-resistant cancer. A composition for treating multidrug-resistant cancer comprising a polynucleotide which hybridizes with a human vault-associated vRNA. A method of screening for compositions for treating a patient with multidrug-resistant cancer.
BACKGROUND AND OBJECTIVES: Previous studies have indicated that alcohol consumption is associated with multiple sclerosis (MS) disease progression. We aimed to study the influence of alcohol consumption habits on disease progression and health-related quality of life in MS.
METHODS: We categorized patients from 2 population-based case-control studies by alcohol consumption habits at diagnosis and followed them up to 15 years after diagnosis through the Swedish MS registry regarding changes in the Expanded Disability Status Scale (EDSS) and Multiple Sclerosis Impact Scale 29 (MSIS-29). We used Cox regression models with 95% confidence intervals (CIs) using 24-week confirmed disability worsening, EDSS 3, EDSS 4, and physical and psychological worsening from the patient's perspective as end points.
RESULTS: Our study comprised 9,051 patients with MS, with a mean age of 37.5 years at baseline/diagnosis. Compared with nondrinking, low and moderate alcohol consumption was associated with reduced risk of EDSS-related unfavorable outcomes (hazard ratios between 0.81 and 0.90) and with reduced risk of physical worsening. The inverse association was confined to relapsing-remitting MS and was more pronounced among women. High alcohol consumption did not significantly affect disease progression. The inverse relationship between low-moderate alcohol consumption and disability progression became stronger when we only included those who had not changed their alcohol consumption during follow-up (hazard ratios between 0.63 and 0.71). There were no differences in measures of disability at baseline between drinkers who continued drinking alcohol after diagnosis and those who later discontinued. Our findings speak against bias due to reverse causation.
DISCUSSION: Low and moderate alcohol consumption was associated with more favorable outcomes in relapsing-remitting MS, compared with nondrinking, while there was no significant influence of high alcohol consumption on disease outcomes.
Etravirine Dosed by weight up to a maximum dose of 200 milligram (mg) bid until switched to an etravirine (ETR)-based treatment regimens (i.e. commercially available and reimbursed, or accessible through another source) or local standard of care, as appropriate.
BMI calculation was calculated with the equation "body weight (kg) / height (m)2" using body weight and height measurement results. BMI was evaluated according to the World Health Organization's BMI Z score classification for ages 5-19. Accordingly, those with a BMI z score above +2 SD are defined as obese.
The SP7 gene encodes a zinc finger transcription factor (Osterix), which is a member of the Sp subfamily of sequence-specific DNA-binding proteins, playing an important role in osteoblast differentiation and maturation. SP7 pathogenic variants have been described in association with different allelic disorders. Monoallelic or biallelic SP7 variants cause Osteogenesis imperfecta type XII (OI12), a very rare condition characterized by recurrent fractures, skeletal deformities, undertubulation of long bones, hearing loss, no dentinogenesis imperfecta, and white sclerae. Monoallelic or biallelic SP7 variants may also cause sclerotic skeletal dysplasias (SSD), partially overlapping with Juvenile Paget's disease and craniodiaphyseal dysplasia, characterized by skull hyperostosis, long bones sclerosis, large ribs and clavicles, and possible recurrent fractures. Here, we report the long-term follow-up of an 85-year-old woman presenting with a complex bone disorder including features of either OI12 (bone fragility with multiple fractures, severe deformities and short stature) or SSD (striking skull hyperostosis with optic atrophy, very large ribs and clavicles and long bones sclerosis). Exome sequencing showed previously undescribed biallelic loss of function variants in the SP7 gene: NM_001173467.2(SP7): c.359_362del, p.(Asp120Valfs*11); NM_001173467.2(SP7): c.1163_1174delinsT, p.(Pro388Leufs*33). RT-qPCR confirmed a severely reduced SP7 transcription compared to controls. Our report provides new insights into the clinical and molecular features and long-term outcome of SP7-related bone disorders (SP7-BD), suggesting a continuum phenotypic spectrum characterized by bone fragility, undertubulation of long bones, scoliosis, and very heterogeneous bone mineral density ranging from osteoporosis to osteosclerosis.
For the encapsulation of cells or biological/chemical substances, they are formed by a jet into small and spherical particles through vibration in an immobilizing mixture. The vibration is through an injection pump (1,2) containing the mixture, which is on a swing mounting, and linked to an oscillation unit (5). For the encapsulation of cells and other substances, external vibration induces a laminar fluid flow of the immobilizing mixture from the injection pump system, divided into small and spherical particles of identical dimensions. The external vibration is preferably applied to the pump at right angles to the line of the fluid flows. The spray needle (6) of the injection pump (1,2) acts as the jet, extending through a sterile membrane (7) in a hardening vessel (A). The spherical particles pass through an electrical field between the jet and the hardening bath, to be given an electrical charge to repel each other. The injection unit is preferably disposable, and is oscillated at a frequency of 400-5000 Hz, and has an injection rate of 1-50 ml/min.  An Independent claim is included for an apparatus to encapsulate cells and other substances, with a mechanical injection pump suspended in a sprung holder (3,4) to take up vertical forces, and allow a lateral oscillation of the injection pump.
A clear, stable, dry-and-non-sticky feeling antiperspirant having an antiperspirant active, a solvent, and a polar silicone emollient. The antiperspirant active is solubilized in the solvent. The polar silicone emollient has an OH group or polyether or mixture thereof. The polyether has an average length of 6 or less of ethylene oxide, propylene oxide or butylenes oxide groups or mixtures thereof. The polar silicone emollient has a chain of dimethyl siloxane groups ranging in an average total length of 8 to 40 silicone atoms. The polar silicone emollient has a linker which is a hydrocarbon chain of 1 to 8 carbons in average length. The polar silicone emollient represents from about 1% to about 95%, more specifically from about 5% to about 70%, even more specifically from about 10% to about 40% by weight of the antiperspirant. The antiperspirant may be contained in a pressurized or non-pressurized container.
Cefepime 50 mg/kg per dose (up to 2 g/dose) will be administered every 8 hours as 30-minutes IV (at least 3 days of IV cefepime only or IV cefipime followed by oral amoxicillin/clavulanate potassium or ciprofloxacin). Total duration of treatment 10 to 14 days.
Patients who are randomized into the second group will also receive prescriptions for 225 MME's on discharge following their surgery, however their medications will be broken up equally into 3 separate scripts, each for 75 MME's. This corresponds to 3 scripts for #10 pills of 5mg oxycodone/acetaminophen, 3 scripts for #15 pills of 5mg hydrocodone/acetaminophen, or 3 scripts for #10 pills of 7.5mg Morphine. Each script will be post-dated to ensure that patients wait the appropriate amount of time between filling their scripts, and that they cannot fill multiple scripts on the same day or at the same time.
This is designed as a pilot (preliminary) study to evaluate the differences in effects on attention, sleep problems and gastrointestinal tolerance associated with Alzheimer's Disease with two different drugs at two different doses. Patients must have mild to moderate Alzheimer's Disease based on the National Institute of Neurological and Communicative Disorders and Stroke-Alzheimer's Disease and Related Disorders Association (NINCDS-ADRDA) criteria and a Mini-Mental State Examination (MMSE) score of 10 to 24. The trial will consist of a 2-week run-in phase, an 8-week assessment phase, and an extension phase of variable length (6 weeks to 54 weeks). During the study, patients will be randomized (assigned by chance) to receive either galantamine or donepezil. Galantamine will be given by mouth 4mg twice daily for Weeks 1-4 and then 8mg twice daily for Weeks 5-8 and beyond (for participants in the extension). The patients on donezepil will receive 5mg by mouth at bedtime for Weeks 1-4 and then 10mg at bedtime for Weeks 5-8 and beyond. Placebo tablets will be given so that each patient takes two capsules per dose in order to conceal the identity of the drugs. Neither the patient nor the physician will know which drug the patient is receiving. Drug effectiveness will be measured by change in overall functioning of the patient shown by the Clinician's Interview-Based Impression of Change Plus Family Input (CIBIC-Plus). Other tests to evaluate whether the drug is effective will include the change in results of attention tests (Simple Reaction Time \[SRT\], Choice Reaction Time \[CRT\], Verbal Series Attention Test \[VSAT\], and Stroop Test), and in sleep pattern tests (tests that measure movements during sleep \[Actiwatch\] and patterns of sleep such as the caregiver-completed Pittsburgh Sleep Quality Index \[PSQI\] and the Circadian Sleep Inventory for Normal and Pathological States \[CSINAPS\]). Measures of quality of life will include the Alzheimer's Disease Related Quality of Life Scale (ADRQL) and the caregiver-completed Allocation of Caregiver Time Survey (ACTS) and SF-12 Quality of Life Survey. Safety assessment and gastrointestinal tolerability will be based on recording the number and severity of unexpected and undesirable events as well as physical examination and vital signs. The exploratory study hypotheses are that galantamine will be superior to donezepil in improving attention, sleep patterns, and quality of life in patients with mild-to-moderate Alzheimer's disease and that it will be well tolerated by patients.

Patients will receive either galantamine 4mg twice daily by mouth or donepezil 5mg at bedtime . Then, either galantamine 8mg twice daily by mouth or donezepil 10 mg at bedtime by mouth (with placebo dose); the doses are continued into the double-blind extension phase (6 to 54 weeks).
Participants receive the computer-generated, personalized assessment of abilities, risk, and recommended next steps. Participants may seek services as usual over the 3-month period.
Research on estimation and measurement of renal function has been greatly stimulated by the international concept of chronic kidney disease (CKD) and its classification into stages of severity based on the level of glomerular filtration rate (GFR) (National Kidney Foundation KDOQI and ANAES in 2002, KDIGO conference in 2005), and by the development of recommendations for clinical practice according to this stages. Many efforts have focused on the validation of new formula to estimate GFR from endogenous markers. Nevertheless, the performance of these formula is limited by a large inter individual variability, that requires in many cases the use of GFR measurement using exogenous tracers (extreme anthropometric characteristics, abnormal production of endogenous tracers, potential kidney donors, dose adjustment, nephrotoxicity monitoring...). The use of GFR measurement is burdened by a lack of availability due to methodological, biological and regulatory (for radioactive tracers) constraints. That's why a need exists for new validated tracers that will be more accessible and easier to use. Moreover, there are differences between the measurement techniques: single injection of the tracer or concentration equilibrium obtained by continuous infusion; plasma or urinary clearance.

Two new tracers for GFR measurement are here offered for validation: Gd-DOTA and Calcium-EDTA. Gd-DOTA is a macrocyclic paramagnetic contrast product, which can be measured using an ELISA type immunoassay. Although being widely used in radiology with higher doses than those that will be used for GFR measurement in the multi-GFR study, Gd-DOTA has never been involved in systemic nephrogenic fibrosis cases (ProFinest study). Calcium-EDTA has been used for many years for the chelation of heavy metals. Recently, a colorimetric assay for Calcium-EDTA measurement has been developed. Gd-DOTA and Calcium-EDTA clearance for GFR measurement will be compared to inuline clearance in healthy volunteers (25 for each new tracer) and CKD patients (150 for each new tracer).